|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The latter is particularly important in conditions such as Parkinson's disease, where a dopamine precursor is used to treat disease symptoms and highlights that the fate of MAO-A containing dopaminergic neurons may depend on both MAO-A levels and catecholamine substrate availability.
|
30336354 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29335210 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
|
28682929 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant binding affinity of ursolic acid was seen with MAO-A, which indicated its potential role in other neurological disorders, for example, Alzheimer's disease and Parkinson disease besides depression.
|
28034283 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The bis-iminothiazolidinone compounds were investigated in vitro for their inhibition of monoamine oxidase (MAO-A & MAO-B) enzymes with the aim to identify new and distinct pharmacophores for the treatment of neurodegenerative disorders like Parkinson's disease.
|
27863747 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings suggest compounds 4 and 11 be considered as new potent and reversible MAO-A inhibitors or useful lead compounds for the developments of MAO inhibitors for the treatment of disorders like depression, Parkinson's disease and Alzheimer disease.
|
28109809 |
2017 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
|
28418735 |
2017 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
|
28299453 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the effectiveness of eckol and dieckol isolated from the methanolic extract of E. bicyclis against PD by the inhibition of human MAO-A and MAO-B (hMAO-A and hMAO-B).
|
28251489 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The enzyme monoamine oxidases (B and A subtypes, encoded by MAOB and MAOA, respectively) are drug targets in the treatment of Parkinson's disease.
|
29050386 |
2017 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
|
24008922 |
2014 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigate power and type I error rate of the likelihood-based test, using simulated data and apply our method to marker data from the monoamine oxidase A&B genes in families with Parkinson disease.
|
18278816 |
2008 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study.
|
17449559 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two distinct forms of enzyme, encoded by genes MAOA and MAOB located on the X chromosome, have been considered as possible factors in the pathogenesis of Parkinson disease (PD).
|
17044053 |
2006 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The frequency of common haplotypes from MAO-A and -B was different in PD and control group (p = 0.02).
|
14962671 |
2004 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We tested for gender-specific interactions between smoking and genetic polymorphisms of monoamine oxidase B (MAO-B) intron 13 (G or A allele), monoamine oxidase A (MAO-A) EcoRV (Yor N allele), and dopamine D2 recepor (DRD2) Taq1B (B1 or B2 allele) in a case-control study of 186 incident idiopathic Parkinson's disease (PD) cases and 296 age- and gender-matched controls.
|
12428723 |
2002 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, there was no association between MAOA-GT or MAOB-GT polymorphisms and PD.
|
12098640 |
2002 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, the 5HTTLPR but not the MAOA gene promoter-associated polymorphism may be a risk factor for depression in PD patients, while neither polymorphism increases the risk for development of Parkinson's disease itself.
|
11326308 |
2001 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.
|
10643794 |
2000 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, disruption of the MAOA gene was evaluated in males with mental retardation with and without a history of sexually deviant behavior, as well as normal controls, healthy males, and patients with other diseases (Parkinson disease, Lesch-Nyhan syndrome).
|
10050962 |
1999 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings support the hypothesis that the MAOA gene may affect the susceptibility of individuals to PD among MAOA polymorphic loci.
|
9642149 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Contrary to previous reports, our findings could not support the hypothesis that susceptibility to PD is associated with MAOA or MAOB polymorphism.
|
8929994 |
1996 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Another MAOA haplotype was about threefold more common in controls than in patients with PD (p = 0.005).
|
7913737 |
1994 |